You might also be interested in:

Debiopharm International SA Initiates FUZE, a Clinical Trial Phase II study evaluating Debio 1347 in Advanced Solid Tumors harboring an FGFR fusion (PHOTO)

Lausanne, Switzerland (ots) - Patients will be recruited in North America, Europe, South America and the Asia ...

German Gin Brand 'GINSTR' Expands to Asia

HONG KONG (ots) - - Cross-reference: Picture is available - Over the ...

Qingdao, the cradle of The Wandering Earth and Crazy Alien

Qingdao, China (ots) - - Picture available via - - Picture ...

08.02.2008 – 08:08

Marseille-Kliniken AG

euro adhoc: Marseille-Kliniken AG
quarterly or semiannual financial statement / - Turnover increases in 1st half of 2007/2008 fiscal year to EUR 112.1 m - Group result climbs to EUR 12.1 m - Equity ratio climbs to 33.8 %

  Disclosure announcement transmitted by euro adhoc. The issuer is responsible
  for the content of this announcement.

6-month report


Ad hoc release According to § 15 WpHG

Berlin, 8th February 2008. During the first half of the 2007/2008 fiscal year, Marseille-Kliniken AG (Prime Standard, ISIN DE 0007783003, MKA) further enhanced its turnover figures, reporting growth of EUR 4,2 m to EUR 112.1 m (previous year´s figure: EUR 107.9 m). The group annual result by minority interests improved from EUR 2.6 m during the previous year to EUR 12.1 m in the period under review. This represents a result per share in the amount of EUR 1.00, compared with EUR 0.22 the previous year. EBIT improved from EUR 8.2 m to EUR 12.5 m. EBITDAR increased from EUR 31.4 m to EUR 36.9 m. Shareholder equity as per balance sheet rose to EUR 84.5 m, up from EUR 66.5 m in the previous reporting period. This made it possible to increase the equity ratio once again, to 33.8%. The last sale-and-leaseback transaction made it possible to reduce net debt, from EUR 108.4 m in the same period last year to the current figure of EUR 66.4 m.

The capacity utilisation rate for the consolidated group rose from 89.7% to 92.5%.

Adjusted for start-up losses for the costs of care and the costs of rehabilitation-facility downtime, the result according to DVFA/SG fell slightly, down EUR 0.4 m from EUR 7.0 m to its current level of EUR 6.6 m. While the rehabilitation area was able to improve its result by EUR 0.6 m for a balanced result, the result in the care area was EUR 1.0 m lower. This was due to planned expenditures in the quality management area, with the aim of further improvements in bed occupancy, coupled with early servicing measures totalling EUR 0.7 m. In addition to this, the increase in energy prices, EUR 0.5 m, was for the most part of temporary effect as approx. 60% of the additional energy costs were the consequence of lower average temperatures during the reporting period and the resultant increase in energy consumption. According to DVFA/SG, the result per share reached EUR 0.55, compared with EUR 0.63 during the comparable period a year before. At the close of the reporting period, EBITDAR was EUR 31.5 m, after EUR 33.1 m on the previous year. EBIT fell from EUR 12.3 m to its current level, EUR 10.0 m.

The core segment of care is growing and was able to register growth of EUR 5.0 m in turnover, for a total of EUR 86.8 m, compared with EUR 81.8 m on the previous year. In terms of the result according to DVFA/SG, the care segment attained a result of EUR 6.6 m (previous year: EUR 7.6 m). Capacity utilisation improved over the previous year, to 93.6% (previous year´s figure: 92.6%).

In the rehabilitation area, the positive trend of the first quarter continued. As a result of capacity reductions, turnover fell to EUR 25.3 m (previous year: EUR 26.1 m). Capacity utilisation had a positive effect, with a market 11.7% rise from 77.4% during the previous year to 89.9% for the period under review. The result according to DVFA/SG is balanced, representing a EUR 0.6 m improvement over the previous year (previous year´s figure: EUR -0.6 m). The company continues to pursue the objective of finding a partner or buyer for its rehabilitation area.

During the fiscal year in progress, three new facilities were opened with a total of 310 beds (in Potsdam, Schömberg and Düsseldorf). Additional locations are in the construction stage; bed capacity will also be added as the company develops its assisted living offerings in the care segment. In the reporting period under review, Marseille-Kliniken AG was able to expand its total number of beds to 8,899 (+287), of which more than 85% are to be found in the care area.

For the entire 2007/2008 fiscal year, the company remains committed to reaching its forecast turnover figure of EUR 240 m, EBIT of EUR 24 m and pre-tax earnings of EUR 18 m. The positive trend in occupancy of the company´s care facilities will continue: the specialisation already successfully completed, together with the company´s verifiable quality management, offers advantages over the competition. Specifically, here speedier occupancy of existing expansion facilities, compared with the both first half-year and the same period in the previous year, will result in marked growth in turnover and falling start-up losses. Rehabilitation has successfully weathered the turn of the tide and has been trimmed to a sustainable core level in terms of capacities. Following the first half-year, it can be anticipated that the results in the rehabilitation area will no longer place the group under a strain during the fiscal year in progress. Under its concept for Assisted Living, the company plans a distinct expansion of capacities and the opening of additional facilities during the current calendar year. In the area of in-patient care, three additional facilities with a total of 430 beds are currently under construction.

Effective immediately, the complete Letter to Shareholders for the first half of the 2007/2008 fiscal year can be found online, at

End of the ad hoc release

end of announcement                               euro adhoc

Further inquiry note:

For further information, please contact:

Marseille-Kliniken AG Hillermann Consulting
Axel Hölzer Christian Hillermann
CEO Investor Relations for Marseille-Kliniken AG
Alte Jakobstraße 79/80 Poststraße 14/16
D-10709 Berlin, Germany D-20354 Hamburg, Germany
Tel.: +49 (0)30 / 246 32-400 Tel.: +49 (0)40 / 320 279 10
Fax: +49 (0)30 / 246 32-401 Fax: +49 (0)40 / 320 279 114

Branche: Pharmaceuticals
ISIN: DE0007783003
WKN: 778300
Index: CDAX, Classic All Share, Prime All Share
Börsen: Börse Frankfurt / regulated dealing/prime standard
Börse Berlin / free trade
Börse Stuttgart / free trade
Börse Düsseldorf / free trade
Börse Hamburg / regulated dealing

Original content of: Marseille-Kliniken AG, transmitted by news aktuell

All Releases
Subscribe to Marseille-Kliniken AG
  • Printable version
  • PDF version

Topics in this relase